Deerfield Management’s Biogen BIIB Stock Holding History

Deerfield Management’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-500,000	Closed	-$102M	–	128
2022 Q2	$102M	Buy	+500,000	New	+$102M	2.1%	11

Other funds holding BIIB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Deerfield Management's BIIB Position: Q4 2024 in Review

Deerfield Management sold out of Biogen (BIIB) in Q4 2024, closing a stake of 3,504 shares — an estimated $679K sold.

Deerfield Management first reported a position in BIIB in Q1 2014 and held it in 7 quarters. The position peaked at $110M in Q4 2020. 874 funds tracked by Wall St. Rank hold BIIB as of Q4 2024.

Deerfield Management reported no remaining Biogen position as of Q4 2024 after selling out during the quarter.
Deerfield Management sold 3,504 Biogen shares in Q4 2024, an estimated $679K.
Deerfield Management first reported a position in Biogen in Q1 2014 and held it in 7 quarters.
Deerfield Management's Biogen position peaked at $110M in Q4 2020.
874 funds tracked by Wall St. Rank held Biogen as of Q4 2024.

Based on Deerfield Management's 13F filing for Q4 2024, filed 14 Feb 2025.